TY - JOUR
T1 - Cardiovascular pharmacotherapy in patients with marfan syndrome
AU - Yetman, Anji T.
N1 - Funding Information:
The authors would like to acknowledge the continuous support of the Industrial Advisory Board member companies of the Center for Grinding Research and Development, especially GM Delphi Chassis Systems, The Torrington Company, and Cincinnati Milacron. Mr. G. Petrosky's help in conducting centerless grinding tests is also gratefully acknowledged.
PY - 2007
Y1 - 2007
N2 - The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.
AB - The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.
UR - http://www.scopus.com/inward/record.url?scp=34249025728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249025728&partnerID=8YFLogxK
U2 - 10.2165/00129784-200707020-00003
DO - 10.2165/00129784-200707020-00003
M3 - Review article
C2 - 17503882
AN - SCOPUS:34249025728
SN - 1175-3277
VL - 7
SP - 117
EP - 126
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 2
ER -